Last updated: October 25, 2023
Sponsor: Gelb, Arthur F., M.D.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Cystic Fibrosis
Lung Disease
Scar Tissue
Treatment
spirometry
Clinical Study ID
NCT03839992
MHS #843-18
Ages 5-40 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: Heterozygote or homozygote patients with cystic fibrosis with normal routine prebronchodilator spirometry including normal FEV1(L), FVC(L) and FEV1/FVC%.
Exclusion
Exclusion Criteria:Heterozygote or homozygote patients with cystic fibrosis with ABNORMALroutine pre bronchodilator spirometry
Study Design
Total Participants: 100
Treatment Group(s): 1
Primary Treatment: spirometry
Phase:
Study Start date:
April 25, 2018
Estimated Completion Date:
November 25, 2027
Study Description
Connect with a study center
Arthur F Gelb MD
Lakewood, California 90712
United StatesActive - Recruiting
Miller Children's Hospital and Long Beach Medical Center
Long Beach, California 90806
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.